Ua hoʻolaha ʻo Athena Bioscience, LLC i nā hoʻolālā no ka hoʻolaha kalepa ʻana o Nexiclon XR, ʻo ia wale nō nā papa clonidine i hoʻokuʻu ʻia i kēlā me kēia lā i hōʻike ʻia no ka mālama ʻana i ka hypertension. Hoʻomaka ʻia ka hoʻomaka ʻana no ʻApelila 1 ma nā mokuʻāina he 2021 US.
Ma ka awelika, ʻo 50% wale nō o nā mākua e pili ana i nā lāʻau maʻi maʻi maʻi2, a i ka hihia o ke koko kiʻekiʻe (BP), pili nā pae haʻahaʻa o ka pili ʻana me ka ʻoi aku ka maikaʻi o ka mana BP a me nā hopena ʻino, e like me ka hahau ʻana, myocardial infarction, heart failure, a make.3-5 Hāʻawi ʻo Nexiclon XR i nā pono lapaʻau antihypertensive like o ka clonidine hoʻokuʻu koke i loko o kahi papa kūpono, hoʻokahi lā i kēlā me kēia lā.6
"Ke manaʻoʻiʻo nei mākou hiki i ka ʻoluʻolu o ka papa hoʻokahi i kēlā me kēia lā ke kōkua i ka hoʻonui ʻana i ka mālama ʻana i nā lāʻau lapaʻau," wahi a Jeff Bryant, Luna Nui o Athena. "ʻO ka hoʻokō ʻoi aku ka maikaʻi e hāʻawi i nā hopena therapeutic i hoʻomaikaʻi ʻia no ka poʻe e loaʻa ana i ka hypertension."
"ʻO ka hoʻomaka ʻana o Nexiclon XR e hōʻike ana i ka kūleʻa mau o Tris i ka lawe ʻana i nā lāʻau lapaʻau ʻenehana like ʻole i ka mākeke," wahi a Tris CEO Ketan Mehta. "Ma muli o kā lākou moʻolelo i hōʻoia ʻia, hauʻoli mākou ʻo Athena kā mākou hoa, e hoʻolaha ana i kēia huahana cardiovascular koʻikoʻi." Hoʻokumu ʻia ʻo Nexiclon ma ka Tris's LiquiXR® ʻenehana lawe lāʻau lapaʻau, kahi i alakaʻi ai i ka hoʻomohala ʻana i nā huahana mua-i-kākoʻo.
He aha e lawe ʻia mai kēia ʻatikala:
- Ma ka awelika, ʻo 50% wale nō o nā mākua e pili ana i nā lāʻau maʻi maʻi mau loa2, a i ka hihia o ke koko kiʻekiʻe (BP), pili nā pae haʻahaʻa o ka pili ʻana me ka ʻoi aku ka maikaʻi o ka hoʻomalu BP a me nā hopena ʻino, e like me ka hahau ʻana, myocardial infarction, heart failure, a make.
- "Ke manaʻoʻiʻo nei mākou hiki i ka ʻoluʻolu o ka papa hoʻokahi i kēlā me kēia lā ke kōkua i ka hoʻonui ʻana i ka mālama ʻana o nā mea maʻi i nā lāʻau lapaʻau,".
- Hoʻonohonoho ʻia ka hoʻokuʻu ʻana no ʻApelila 2022 ma nā 50 U.
